Vaxart/ US92243A2006 /

7/1/2022 9:59:55 PM	Chg. +0.25	Volume	Bid-	Ask-	High	Low
3.75USD	+7.00%	35,377 Turnover: 130,845.79	-Bid Size: -	-Ask Size: -	3.75	3.48

GlobeNewswire 2/24 Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2/14 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

GlobeNewswire 1/4 Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire 12/16/2021 Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

GlobeNewswire 12/1/2021 Vaxart Announces Acquisition of Second GMP Manufacturing Facility

GlobeNewswire 11/23/2021 Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021

GlobeNewswire 11/18/2021 Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an...

GlobeNewswire 11/16/2021 Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challen...

GlobeNewswire 11/11/2021 Vaxart to Participate at Upcoming Conferences

GlobeNewswire 11/4/2021 Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire 10/19/2021 SHAREHOLDER ALERT: Morris Kandinov Investigating TSN, VXRT, APYX, and EHTH; Shareholders are Encoura...

GlobeNewswire 7/7/2021 Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir An...

GlobeNewswire 6/7/2021 Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

GlobeNewswire 5/27/2021 Vaxart to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire 5/20/2021 LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

GlobeNewswire 5/7/2021 Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

GlobeNewswire 5/4/2021 Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

GlobeNewswire 5/3/2021 New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Oth...

GlobeNewswire 5/3/2021 Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 4/29/2021 Vaxart to Present at the World Vaccine Congress Washington 2021

GlobeNewswire 4/26/2021 Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vacci...

GlobeNewswire 4/23/2021 Vaxart Appoints David Wheadon, M.D., to its Board of Directors

GlobeNewswire 4/22/2021 Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of American...

GlobeNewswire 4/1/2021 LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors

GlobeNewswire 3/4/2021 Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference